Day: December 2, 2023

HII’s Ingalls Shipbuilding Christens Amphibious Assault Ship Bougainville (LHA 8)

HII’s Ingalls Shipbuilding Christens Amphibious Assault Ship Bougainville (LHA 8)

Bougainville (LHA 8) Christening Ship’s sponsor Ellyn S. Dunford christened the Bougainville (LHA 8) at HII’s Ingalls Shipbuilding. Pictured from left is Under Secretary of the Navy Erik Raven, Ingalls Shipbuilding President Kari Wilkinson, Prospective Commanding Officer, Bougainville (LHA 8) Capt. Harry Marsh, U.S. Navy, and Ship’s Sponsor Ellyn S. Dunford. PASCAGOULA, Miss., Dec. 02, 2023 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division christened the Navy’s third America-class amphibious assault ship Bougainville (LHA 8) today. “Today is not only a day to celebrate our namesake, representatives of the successful outcome of a World War II campaign, but also the team work and collaboration of our United States Navy and Marine Corps that enabled it,” Ingalls Shipbuilding President Kari Wilkinson said....

Continue reading

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “Xenon will have another strong presence at AES this year, with many presentations and activities aimed at raising awareness about our XEN1101 program with the epileptologists and neurologists in attendance. Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial. These new data demonstrate impressive seizure freedom rates, including almost one in four patients who were on treatment for at least...

Continue reading

Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa

Scatec at COP28: Accelerating renewable energy transition from Egypt to South Africa

Dubai, 2 December 2023: This week, Scatec ASA, a leading renewable energy company, is actively engaging in the UN Climate Change Conference in Dubai (COP28). Our focus is to underscore renewable energy as an unequivocal solution to climate change and emphasise the critical need for increased green energy investments in emerging markets. COP28 serves as a pivotal platform for global stakeholders to reinforce commitments aimed at averting catastrophic consequences of climate change. Scatec aligns with climate experts in stressing the urgency of the situation and the imperative to continue advancing towards the objectives outlined in the Paris Agreement. There’s no time to waste, and collective progress is crucial for safeguarding our planet’s future. “We are at COP28 to highlight the key role renewable energy must play in our...

Continue reading

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA...

Continue reading

NaaS Technology Take Center Stage at COP28 to Accelerate Sustainability in Transport Energy Transformation

NaaS Technology Take Center Stage at COP28 to Accelerate Sustainability in Transport Energy Transformation

NaaS Technology Take Center Stage at COP28 to Accelerate Sustainability in Transport Energy Transformation The inauguration of NaaS’s Exhibition Hall follows the company’s first appearance at the Electric Vehicle Innovation Summit (EVIS), held in Abu Dhabi in May 2023, to reaffirm the company’s commitment in supporting EV charging services in the Middle East. Moreover, NaaS’s MOU signing with China Innovation Centre at Dubai Chambers in November underscored the commitment of both parties to collaborating and exploring opportunities to strengthen bilateral economic and commercial relations. The Middle East markets have also shown strong investments in EV charging infrastructure to foster this growth—an encouraging sign that the region is beginning to rapidly transition to electric mobility. DUBAI, UAE, Dec. 01, 2023 (GLOBE NEWSWIRE)...

Continue reading

West Red Lake Gold Announces Sprott’s Investment of US$2,631,463

West Red Lake Gold Announces Sprott’s Investment of US$2,631,463

VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) — West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQX: WRLGF) is pleased to announce that, further to an unsecured convertible promissory note dated August 24, 2023 in the amount of US$5,533,094 for deferred consideration related to the acquisition of Pure Gold Mining Inc. (the “Obligation”) between the Company and a fund managed by Sprott Resource Lending Corp (“Sprott”), the Company has received A Conversion Election Notice from Sprott to convert US$2,631,463 of the Obligations into 6,900,000 units in the capital of the Company at a conversion price of C$0.52 per unit (the “Units”), with each Unit consisting of one common share of the Company and one share purchase warrant which is exercisable into one common share of the...

Continue reading

Goldmoney Inc. Announces Closing of Schiff Gold Sale and Cancellation of Securities

Goldmoney Inc. Announces Closing of Schiff Gold Sale and Cancellation of Securities

TORONTO, Dec. 01, 2023 (GLOBE NEWSWIRE) — Goldmoney Inc. (TSX:XAU) (US:XAUMF) (“Goldmoney” or the “Company”), today announces that it has closed the transaction previously announced on September 26, 2023 (the “Transaction”) with PDS Family Hycet Trust (the “Purchaser”) to sell all of its membership interest in its wholly-owned subsidiary, Schiff Gold LLC. (“SGL”). Pursuant to the terms of a securities exchange agreement dated December 1, 2023, Goldmoney received 212,600 common shares of Goldmoney (the “Goldmoney Shares”) and 280,000 common share purchase warrants of Goldmoney (the “Goldmoney Warrants” and, together with the Goldmoney Shares, the “Goldmoney Securities”) in consideration for all of Goldmoney’s membership interests in SGL. Goldmoney also received payment of USD$290,000 upon closing of the Transaction. The Goldmoney...

Continue reading

SIERRA ISSUES STOCK OPTIONS

SIERRA ISSUES STOCK OPTIONS

Surrey, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) — Sierra Grande Minerals Inc. (the “Company” or “Sierra”) (CSE: SGRO) (OTC: SIERF) (FF: F91Q) announces that it has granted a total of 1,350,000 incentive stock options to certain directors, officers and employees of the Company pursuant to the Company’s Stock Option Plan. The options are exercisable at $0.10 per share and expire five (5) years from the date of grant. ON BEHALF OF THE BOARDSonny Janda, CEO & Directorwww.sierraminerals.com Email Address: info@sierragrowth.com Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes certain statements that constitute “forward-looking...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.